Intercept Pharmaceuticals (NASDAQ:ICPT)‘s stock had its “buy” rating reissued by equities researchers at Wedbush in a report released on Friday. They presently have a $253.00 target price on the biopharmaceutical company’s stock. Wedbush’s price objective would indicate a potential upside of 351.54% from the stock’s previous close.

A number of other brokerages have also commented on ICPT. Cowen reiterated an “outperform” rating and set a $232.00 price target on shares of Intercept Pharmaceuticals in a report on Thursday, September 14th. Goldman Sachs Group reiterated a “neutral” rating and set a $79.00 price target on shares of Intercept Pharmaceuticals in a report on Friday, October 6th. Cantor Fitzgerald reiterated an “underweight” rating and set a $69.00 price target on shares of Intercept Pharmaceuticals in a report on Wednesday, September 13th. Citigroup set a $74.00 price target on Intercept Pharmaceuticals and gave the stock a “hold” rating in a report on Friday, December 29th. Finally, Leerink Swann dropped their price target on Intercept Pharmaceuticals from $120.00 to $66.00 and set a “market perform” rating on the stock in a report on Saturday, September 23rd. Four equities research analysts have rated the stock with a sell rating, ten have issued a hold rating, eleven have assigned a buy rating and one has given a strong buy rating to the company’s stock. Intercept Pharmaceuticals has a consensus rating of “Hold” and an average price target of $141.58.

Intercept Pharmaceuticals (NASDAQ:ICPT) traded down $0.50 during mid-day trading on Friday, hitting $56.03. The stock had a trading volume of 854,500 shares, compared to its average volume of 1,184,167. Intercept Pharmaceuticals has a 52 week low of $54.98 and a 52 week high of $135.59. The company has a quick ratio of 5.95, a current ratio of 5.95 and a debt-to-equity ratio of 3.15. The company has a market capitalization of $1,450.00, a price-to-earnings ratio of -3.79 and a beta of -2.05.

Intercept Pharmaceuticals (NASDAQ:ICPT) last posted its earnings results on Wednesday, November 1st. The biopharmaceutical company reported ($2.89) earnings per share for the quarter, beating the Zacks’ consensus estimate of ($3.48) by $0.59. Intercept Pharmaceuticals had a negative return on equity of 176.51% and a negative net margin of 344.74%. The company had revenue of $41.33 million for the quarter, compared to analyst estimates of $36.95 million. During the same quarter last year, the company earned ($3.59) earnings per share. The company’s revenue for the quarter was up 697.9% on a year-over-year basis. research analysts expect that Intercept Pharmaceuticals will post -13.36 EPS for the current year.

Several hedge funds and other institutional investors have recently made changes to their positions in ICPT. Rhumbline Advisers grew its position in shares of Intercept Pharmaceuticals by 3.7% in the second quarter. Rhumbline Advisers now owns 20,244 shares of the biopharmaceutical company’s stock valued at $2,451,000 after purchasing an additional 713 shares in the last quarter. State of Wisconsin Investment Board grew its position in shares of Intercept Pharmaceuticals by 7.9% in the second quarter. State of Wisconsin Investment Board now owns 3,567 shares of the biopharmaceutical company’s stock valued at $432,000 after purchasing an additional 260 shares in the last quarter. SG Americas Securities LLC purchased a new position in shares of Intercept Pharmaceuticals in the second quarter valued at $235,000. Bank of New York Mellon Corp grew its position in shares of Intercept Pharmaceuticals by 4.8% in the second quarter. Bank of New York Mellon Corp now owns 71,549 shares of the biopharmaceutical company’s stock valued at $8,662,000 after purchasing an additional 3,247 shares in the last quarter. Finally, Legal & General Group Plc grew its position in shares of Intercept Pharmaceuticals by 10.4% in the second quarter. Legal & General Group Plc now owns 5,974 shares of the biopharmaceutical company’s stock valued at $723,000 after purchasing an additional 561 shares in the last quarter. Institutional investors own 73.76% of the company’s stock.

ILLEGAL ACTIVITY NOTICE: This story was originally published by American Banking News and is the sole property of of American Banking News. If you are viewing this story on another website, it was copied illegally and reposted in violation of United States & international trademark and copyright legislation. The original version of this story can be accessed at https://www.americanbankingnews.com/2018/01/05/wedbush-reaffirms-buy-rating-for-intercept-pharmaceuticals-icpt.html.

About Intercept Pharmaceuticals

Intercept Pharmaceuticals, Inc is a biopharmaceutical company. The Company is focused on the development and commercialization of therapeutics to treat non-viral, progressive liver diseases. The Company’s product candidates have the potential to treat orphan and more prevalent diseases for which there are limited therapeutic solutions.

Analyst Recommendations for Intercept Pharmaceuticals (NASDAQ:ICPT)

Receive News & Ratings for Intercept Pharmaceuticals Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Intercept Pharmaceuticals and related companies with MarketBeat.com's FREE daily email newsletter.